<!DOCTYPE html>
<html lang="th">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Submassive PE Analysis - Full Report</title>
    <style>
        /* --- GLOBAL STYLES --- */
        body {
            font-family: 'Arial', sans-serif;
            margin: 20px;
            background-color: #f5f5f5;
            color: #333;
        }
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background-color: white;
            padding: 30px;
            border-radius: 5px;
            box-shadow: 0 0 10px rgba(0,0,0,0.1);
            min-height: 80vh;
        }

        /* --- NAVIGATION TABS --- */
        .nav-tabs {
            display: flex;
            justify-content: center;
            margin-bottom: 30px;
            border-bottom: 2px solid #bdc3c7;
            padding-bottom: 0;
        }
        .nav-btn {
            padding: 15px 30px;
            font-size: 16px;
            font-weight: bold;
            cursor: pointer;
            background-color: #ecf0f1;
            border: 1px solid #bdc3c7;
            border-bottom: none;
            margin: 0 5px;
            border-radius: 5px 5px 0 0;
            transition: all 0.3s ease;
            color: #7f8c8d;
        }
        .nav-btn:hover {
            background-color: #dfe6e9;
        }
        .nav-btn.active {
            background-color: white;
            color: #2c3e50;
            border-top: 4px solid;
            margin-bottom: -2px; /* Covers the bottom border line */
            padding-bottom: 17px;
        }
        /* Active color for Main Tab */
        .nav-btn.active[onclick*="main"] {
            border-top-color: #3498db;
            color: #3498db;
        }
        /* Active color for Regression Tab */
        .nav-btn.active[onclick*="regression"] {
            border-top-color: #e74c3c;
            color: #e74c3c;
        }

        /* --- VIEW CONTROLS --- */
        .view-section {
            display: none; /* Hidden by default */
            animation: fadeIn 0.5s;
        }
        .view-section.active {
            display: block; /* Show when active */
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }

        /* --- COMMON ELEMENTS --- */
        table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 15px;
            margin-bottom: 30px;
            font-size: 13px;
        }
        td, th {
            border: 1px solid #bdc3c7;
            padding: 10px;
            text-align: left;
        }
        .notes {
            background-color: #fff3cd;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin-top: 20px;
            font-size: 12px;
        }
        .summary {
            background-color: #d5f4e6;
            border-left: 4px solid #27ae60;
            padding: 15px;
            margin-top: 20px;
            font-size: 12px;
        }

        /* --- STYLES SPECIFIC TO MAIN VIEW (Blue Theme) --- */
        #view-main h1 {
            color: #2c3e50;
            border-bottom: 3px solid #3498db;
            padding-bottom: 10px;
            text-align: center;
        }
        #view-main h2 {
            color: #34495e;
            margin-top: 30px;
            border-left: 5px solid #3498db;
            padding-left: 15px;
        }
        #view-main table tr:first-child {
            background-color: #3498db;
            color: white;
            font-weight: bold;
        }
        #view-main table tr:nth-child(even) { background-color: #ecf0f1; }
        #view-main table tr:hover { background-color: #d5e8f7; }
        #view-main .p-value-significant { color: #e74c3c; font-weight: bold; }
        #view-main .key-finding { color: #c0392b; font-weight: bold; }

        /* --- STYLES SPECIFIC TO REGRESSION VIEW (Red Theme) --- */
        #view-regression h1 {
            color: #2c3e50;
            border-bottom: 3px solid #e74c3c;
            padding-bottom: 10px;
            text-align: center;
        }
        #view-regression h2 {
            color: #34495e;
            margin-top: 30px;
            border-left: 5px solid #e74c3c;
            padding-left: 15px;
        }
        #view-regression table tr:first-child {
            background-color: #e74c3c;
            color: white;
            font-weight: bold;
        }
        #view-regression table tr:nth-child(even) { background-color: #ecf0f1; }
        #view-regression table tr:hover { background-color: #fadbd8; }
        #view-regression td, #view-regression th { text-align: right; }
        #view-regression td:first-child, #view-regression th:first-child { text-align: left; }
        
        /* Special Boxes for Regression View */
        .model-box {
            background-color: #fdeef4;
            border-left: 4px solid #e74c3c;
            padding: 15px;
            margin: 20px 0;
        }
        .metric-box {
            background-color: #e8f8f5;
            border-left: 4px solid #27ae60;
            padding: 15px;
            margin: 20px 0;
        }
        .p-value-sig {
            color: #c0392b;
            font-weight: bold;
        }

        /* --- NEW STYLES FOR DISCUSSION SECTION --- */
        .discussion-box {
            background-color: #f4f6f7;
            border-left: 5px solid #34495e;
            padding: 20px;
            margin: 20px 0;
            font-size: 13px;
            line-height: 1.6;
        }
        .discussion-box h3 { margin-top: 0; color: #2c3e50; }
        
        .risk-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin-top: 20px;
        }
        .risk-card {
            padding: 20px;
            border-radius: 5px;
            border: 1px solid;
        }
        .risk-high {
            background-color: #ffebee;
            border-color: #ef9a9a;
        }
        .risk-high h3 { color: #c62828; margin-top: 0; }
        .risk-high ul { color: #b71c1c; }
        
        .risk-low {
            background-color: #e8f5e9;
            border-color: #a5d6a7;
        }
        .risk-low h3 { color: #2e7d32; margin-top: 0; }
        .risk-low ul { color: #1b5e20; }

        @media (max-width: 768px) {
            .risk-grid { grid-template-columns: 1fr; }
        }

        footer {
            margin-top: 40px; 
            padding-top: 20px; 
            border-top: 1px solid #bdc3c7; 
            text-align: center; 
            color: #7f8c8d; 
            font-size: 11px;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <div class="nav-tabs">
            <button class="nav-btn active" onclick="switchTab('main')">1. Clinical Analysis (Main)</button>
            <button class="nav-btn" onclick="switchTab('regression')">2. Logistic Regression Models</button>
        </div>

        <div id="view-main" class="view-section active">
            <h1>Submassive Pulmonary Embolism (PE) - Clinical Analysis Report</h1>

            <div class="summary">
                <strong>Study Overview:</strong>
                <ul>
                    <li><strong>Total Patients:</strong> 116</li>
                    <li><strong>Survived (Lived):</strong> 97 patients (83.6%)</li>
                    <li><strong>Died:</strong> 19 patients (16.4%)</li>
                    <li><strong>30-day Mortality:</strong> 16.4%</li>
                </ul>
            </div>
    
            <h2>1. DEMOGRAPHIC DATA ANALYSIS</h2>
    <table>
    <tr><th>Variable</th><th>Lived (n=97)</th><th>Died (n=19)</th><th>Test</th><th>p-value</th><th>OR (95% CI)</th><th>Missing</th></tr>
    <tr><td>Age (years)</td><td>57.4±19.7</td><td>58.6±16.5</td><td>t-test</td><td>0.8063</td><td>—</td><td>0/0</td></tr>
    <tr><td>sex: Female</td><td>69 (71.1%)</td><td>10 (52.6%)</td><td>χ²</td><td>0.1891</td><td>2.22</td><td>0/0</td></tr>
    <tr><td>sex: Male</td><td>28 (28.9%)</td><td>9 (47.4%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>race: Asian</td><td>94 (96.9%)</td><td>18 (94.7%)</td><td>χ²</td><td>1.0000</td><td>1.74</td><td>0/0</td></tr>
    <tr><td>race: Caucasian</td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>race: African</td><td>2 (2.1%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>ht: No</td><td>53 (54.6%)</td><td>13 (68.4%)</td><td>χ²</td><td>0.3920</td><td>0.56</td><td>0/0</td></tr>
    <tr><td>ht: Yes</td><td>44 (45.4%)</td><td>6 (31.6%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dlp: No</td><td>71 (73.2%)</td><td>14 (73.7%)</td><td>χ²</td><td>1.0000</td><td>0.98</td><td>0/0</td></tr>
    <tr><td>dlp: Yes</td><td>26 (26.8%)</td><td>5 (26.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dm: No</td><td>77 (79.4%)</td><td>17 (89.5%)</td><td>χ²</td><td>0.4801</td><td>0.45</td><td>0/0</td></tr>
    <tr><td>dm: Yes</td><td>20 (20.6%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>stroke: No</td><td>87 (89.7%)</td><td>19 (100.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>stroke: Yes</td><td>10 (10.3%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>ckd: No</td><td>91 (93.8%)</td><td>17 (89.5%)</td><td>χ²</td><td>0.8511</td><td>1.78</td><td>0/0</td></tr>
    <tr><td>ckd: Yes</td><td>6 (6.2%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>cad: No</td><td>94 (96.9%)</td><td>18 (94.7%)</td><td>χ²</td><td>1.0000</td><td>1.74</td><td>0/0</td></tr>
    <tr><td>cad: Yes</td><td>3 (3.1%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>cirrhosis: No</td><td>91 (93.8%)</td><td>18 (94.7%)</td><td>χ²</td><td>1.0000</td><td>0.84</td><td>0/0</td></tr>
    <tr><td>cirrhosis: Yes</td><td>6 (6.2%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>cnt: No</td><td>96 (99.0%)</td><td>17 (89.5%)</td><td>χ²</td><td>0.1109</td><td>11.29</td><td>0/0</td></tr>
    <tr><td>cnt: Yes</td><td>1 (1.0%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>lung: No</td><td>96 (99.0%)</td><td>19 (100.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>lung: Yes</td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>af: No</td><td>95 (97.9%)</td><td>19 (100.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>af: Yes</td><td>2 (2.1%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>malignancy: No</td><td>74 (76.3%)</td><td>3 (15.8%)</td><td>χ²</td><td class='p-value-significant'>0.0000</td><td>17.16</td><td>0/0</td></tr>
    <tr><td>malignancy: Yes</td><td>23 (23.7%)</td><td>16 (84.2%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>comorbid: None</td><td>23 (23.7%)</td><td>0 (0.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>comorbid: ≥1 medical disease</td><td>74 (76.3%)</td><td>19 (100.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>immobilize: No</td><td>85 (87.6%)</td><td>15 (78.9%)</td><td>χ²</td><td>0.5223</td><td>1.89</td><td>0/0</td></tr>
    <tr><td>immobilize: Yes</td><td>12 (12.4%)</td><td>4 (21.1%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dvt: No</td><td>87 (89.7%)</td><td>17 (89.5%)</td><td>χ²</td><td>1.0000</td><td>1.02</td><td>0/0</td></tr>
    <tr><td>dvt: Yes</td><td>9 (9.3%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dvt: N</td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>ocp: No</td><td>79 (81.4%)</td><td>19 (100.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>ocp: Yes</td><td>18 (18.6%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>smoking: No</td><td>93 (95.9%)</td><td>18 (94.7%)</td><td>χ²</td><td>1.0000</td><td>1.29</td><td>0/0</td></tr>
    <tr><td>smoking: Yes</td><td>4 (4.1%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>sx: No</td><td>91 (93.8%)</td><td>17 (89.5%)</td><td>χ²</td><td>0.8511</td><td>1.78</td><td>0/0</td></tr>
    <tr><td>sx: Yes</td><td>6 (6.2%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>trauma: No</td><td>94 (96.9%)</td><td>18 (94.7%)</td><td>χ²</td><td>1.0000</td><td>1.74</td><td>0/0</td></tr>
    <tr><td>trauma: Yes</td><td>3 (3.1%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    </table>
    
    <div class="notes">
        <strong>Key Findings (Demographics):</strong>
        <ul>
            <li><span class="key-finding">Active malignancy</span> was significantly associated with mortality (χ² p=0.0000, OR=17.16), with 84.2% of deceased patients having active malignancy vs 23.7% of survivors.</li>
            <li>No significant difference in age between groups (mean age: 57.4±19.7 years for survivors vs 58.6±16.5 years for deceased, p=0.8063)</li>
            <li>Respiratory failure was significant risk factor (p=0.0073)</li>
            <li>Gender distribution showed trend toward male predominance in deceased patients (47.4% male died vs 28.9% survived)</li>
        </ul>
    </div>
    
            <h2>2. CLINICAL PRESENTATION ANALYSIS</h2>
    <table>
    <tr><th>Variable</th><th>Lived (n=97)</th><th>Died (n=19)</th><th>Test</th><th>p-value</th><th>OR (95% CI)</th><th>Missing</th></tr>
    <tr><td>desat: No</td><td>43 (44.3%)</td><td>6 (31.6%)</td><td>χ²</td><td>0.4383</td><td>1.73</td><td>0/0</td></tr>
    <tr><td>desat: Yes</td><td>54 (55.7%)</td><td>13 (68.4%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dyspnea_rest: No</td><td>63 (64.9%)</td><td>8 (42.1%)</td><td>χ²</td><td>0.1071</td><td>2.55</td><td>0/0</td></tr>
    <tr><td>dyspnea_rest: Yes</td><td>34 (35.1%)</td><td>11 (57.9%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dyspnea_exertion: No</td><td>12 (12.4%)</td><td>2 (10.5%)</td><td>χ²</td><td>1.0000</td><td>1.20</td><td>0/0</td></tr>
    <tr><td>dyspnea_exertion: Yes</td><td>85 (87.6%)</td><td>17 (89.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>cough: No</td><td>77 (79.4%)</td><td>13 (68.4%)</td><td>χ²</td><td>0.4552</td><td>1.78</td><td>0/0</td></tr>
    <tr><td>cough: Yes</td><td>13 (13.4%)</td><td>5 (26.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>cough: Hemoptysis</td><td>7 (7.2%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>syncope: No</td><td>76 (78.4%)</td><td>15 (78.9%)</td><td>χ²</td><td>1.0000</td><td>0.97</td><td>0/0</td></tr>
    <tr><td>syncope: Yes</td><td>21 (21.6%)</td><td>4 (21.1%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>chestpain: No</td><td>79 (81.4%)</td><td>15 (78.9%)</td><td>χ²</td><td>1.0000</td><td>1.17</td><td>0/0</td></tr>
    <tr><td>chestpain: Yes</td><td>18 (18.6%)</td><td>4 (21.1%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>edema: No</td><td>74 (76.3%)</td><td>12 (63.2%)</td><td>χ²</td><td>0.3634</td><td>1.88</td><td>0/0</td></tr>
    <tr><td>edema: Yes</td><td>23 (23.7%)</td><td>7 (36.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>palpitation: No</td><td>78 (80.4%)</td><td>17 (89.5%)</td><td>χ²</td><td>0.5404</td><td>0.48</td><td>0/0</td></tr>
    <tr><td>palpitation: Yes</td><td>19 (19.6%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>fever: No</td><td>92 (94.8%)</td><td>16 (84.2%)</td><td>χ²</td><td>0.2389</td><td>3.45</td><td>0/0</td></tr>
    <tr><td>fever: Yes</td><td>5 (5.2%)</td><td>3 (15.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>resp: No</td><td>90 (92.8%)</td><td>13 (68.4%)</td><td>χ²</td><td class='p-value-significant'>0.0073</td><td>5.93</td><td>0/0</td></tr>
    <tr><td>resp: Yes</td><td>7 (7.2%)</td><td>6 (31.6%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    </table>
    
    <div class="notes">
        <strong>Key Findings (Clinical Presentation):</strong>
        <ul>
            <li><span class="key-finding">Respiratory failure</span> was significantly associated with mortality (p=0.0073, OR=5.93), with 31.6% of deceased patients presenting with respiratory failure vs only 7.2% of survivors.</li>
            <li>Dyspnea at rest showed trend toward higher incidence in deceased patients (57.9% vs 35.1%, p=0.1071)</li>
            <li>Most patients presented with dyspnea on exertion (87.6% in survivors, 89.5% in deceased)</li>
            <li>Fever was more common in deceased patients (15.8% vs 5.2%)</li>
        </ul>
    </div>
    
            <h2>3. PHYSICAL EXAMINATION FINDINGS</h2>
    <table>
    <tr><th>Variable</th><th>Lived (n=97)</th><th>Died (n=19)</th><th>Test</th><th>p-value</th><th>OR (95% CI)</th><th>Missing</th></tr>
    <tr><td>Heart Rate (bpm)</td><td>102.6±20.9</td><td>109.8±19.7</td><td>t-test</td><td>0.1667</td><td>—</td><td>0/0</td></tr>
    <tr><td>Respiratory Rate (per min)</td><td>22.8±4.8</td><td>25.3±4.1</td><td>t-test</td><td class='p-value-significant'>0.0373</td><td>—</td><td>0/0</td></tr>
    <tr><td>Oxygen Saturation (%)</td><td>91.4±6.7</td><td>89.3±5.3</td><td>t-test</td><td>0.2001</td><td>—</td><td>1/0</td></tr>
    <tr><td>jvd: No</td><td>91 (93.8%)</td><td>18 (94.7%)</td><td>χ²</td><td>1.0000</td><td>0.84</td><td>0/0</td></tr>
    <tr><td>jvd: Yes</td><td>6 (6.2%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>leg_edema: No</td><td>65 (67.0%)</td><td>12 (63.2%)</td><td>χ²</td><td>0.9525</td><td>1.18</td><td>0/0</td></tr>
    <tr><td>leg_edema: Yes</td><td>32 (33.0%)</td><td>7 (36.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    </table>
    
    <div class="notes">
        <strong>Key Findings (Physical Examination):</strong>
        <ul>
            <li><span class="key-finding">Respiratory Rate</span> was significantly higher in deceased patients (25.3±4.1 per min vs 22.8±4.8, p=0.0373)</li>
            <li>Heart rate was elevated in both groups but higher in deceased patients (109.8±19.7 vs 102.6±20.9 bpm, p=0.1667)</li>
            <li>Oxygen saturation was lower in deceased patients (89.3±5.3% vs 91.4±6.7%, p=0.2001)</li>
            <li>Jugular vein distension and leg edema showed no significant difference between groups</li>
        </ul>
    </div>
    
            <h2>4. LABORATORY VALUES</h2>
    <table>
    <tr><th>Variable</th><th>Lived (n=97)</th><th>Died (n=19)</th><th>Test</th><th>p-value</th><th>Missing (L/D)</th></tr>
    <tr><td>pH</td><td>7.44±0.07</td><td>7.43±0.07</td><td>t-test</td><td>0.5250</td><td>37/4</td></tr>
    <tr><td>PaO2</td><td>84.27±38.53</td><td>73.01±19.75</td><td>t-test</td><td>0.2956</td><td>43/5</td></tr>
    <tr><td>PF ratio</td><td>285.08±77.95</td><td>240.84±110.01</td><td>t-test</td><td>0.0882</td><td>43/5</td></tr>
    <tr><td>PCO2</td><td>29.92±7.82</td><td>29.65±6.72</td><td>t-test</td><td>0.9050</td><td>37/4</td></tr>
    <tr><td>Lactate</td><td>1.76±0.98</td><td>2.45±1.55</td><td>t-test</td><td class='p-value-significant'>0.0256</td><td>31/2</td></tr>
    <tr><td>Hemoglobin</td><td>12.11±2.32</td><td>10.86±1.82</td><td>t-test</td><td class='p-value-significant'>0.0283</td><td>0/0</td></tr>
    <tr><td>Hematocrit</td><td>37.42±6.99</td><td>33.04±5.54</td><td>t-test</td><td class='p-value-significant'>0.0114</td><td>0/0</td></tr>
    <tr><td>Platelet</td><td>232.04±81.97</td><td>3904.00±14819.65</td><td>t-test</td><td class='p-value-significant'>0.0144</td><td>0/0</td></tr>
    <tr><td>Creatinine</td><td>0.92±0.36</td><td>0.84±0.51</td><td>t-test</td><td>0.3957</td><td>0/0</td></tr>
    <tr><td>Bicarbonate</td><td>21.76±3.18</td><td>20.63±3.47</td><td>t-test</td><td>0.1652</td><td>0/0</td></tr>
    <tr><td>Albumin</td><td>3.60±0.49</td><td>2.86±0.49</td><td>t-test</td><td class='p-value-significant'>0.0000</td><td>1/0</td></tr>
    <tr><td>PT</td><td>12.79±1.03</td><td>15.19±2.70</td><td>t-test</td><td class='p-value-significant'>0.0000</td><td>0/0</td></tr>
    <tr><td>PTT</td><td>25.17±3.47</td><td>28.04±5.49</td><td>t-test</td><td class='p-value-significant'>0.0038</td><td>0/0</td></tr>
    <tr><td>INR</td><td>1.13±0.10</td><td>1.36±0.25</td><td>t-test</td><td class='p-value-significant'>0.0000</td><td>0/0</td></tr>
    <tr><td>Troponin</td><td>338.05±743.04</td><td>242.49±247.49</td><td>t-test</td><td>0.6239</td><td>7/4</td></tr>
    <tr><td>NTproBNP</td><td>3817.04±4831.05</td><td>4586.64±5251.09</td><td>t-test</td><td>0.5663</td><td>14/3</td></tr>
    <tr><td>D-dimer</td><td>6237.05±2103.24</td><td>6107.25±3147.04</td><td>t-test</td><td>0.9105</td><td>56/15</td></tr>
    </table>
    
    <div class="notes">
        <strong>Key Findings (Laboratory Values):</strong>
        <ul>
            <li><span class="key-finding">Albumin</span> was significantly lower in deceased patients (2.86±0.49 vs 3.60±0.49, p=0.0000)</li>
            <li><span class="key-finding">INR</span> was significantly elevated in deceased patients (1.36±0.25 vs 1.13±0.10, p=0.0000)</li>
            <li><span class="key-finding">PT</span> was significantly prolonged in deceased patients (15.19±2.70 vs 12.79±1.03, p=0.0000)</li>
            <li><span class="key-finding">PTT</span> was significantly elevated in deceased patients (28.04±5.49 vs 25.17±3.47, p=0.0038)</li>
            <li><span class="key-finding">Hemoglobin</span> was significantly lower in deceased patients (10.86±1.82 vs 12.11±2.32, p=0.0283)</li>
            <li><span class="key-finding">Hematocrit</span> was significantly lower in deceased patients (33.04±5.54 vs 37.42±6.99, p=0.0114)</li>
            <li><span class="key-finding">Lactate</span> was elevated in deceased patients (2.45±1.55 vs 1.76±0.98, p=0.0256)</li>
            <li>PF ratio showed trend toward lower values in deceased patients (240.84±110.01 vs 285.08±77.95, p=0.0882)</li>
        </ul>
    </div>
    
            <h2>5. INVESTIGATION FINDINGS</h2>
    <table>
    <tr><th>Variable</th><th>Lived (n=97)</th><th>Died (n=19)</th><th>Test</th><th>p-value</th><th>OR (95% CI)</th><th>Missing (L/D)</th></tr>
    <tr><td>sinus: No</td><td>5 (5.2%)</td><td>1 (5.3%)</td><td>χ²</td><td>1.0000</td><td>0.98</td><td>0/0</td></tr>
    <tr><td>sinus: Yes</td><td>92 (94.8%)</td><td>18 (94.7%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>rate: <60</td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>rate: 60-100</td><td>33 (34.0%)</td><td>3 (15.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>rate: 100-150</td><td>63 (64.9%)</td><td>16 (84.2%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>s1q3t3: No</td><td>64 (66.0%)</td><td>16 (84.2%)</td><td>χ²</td><td>0.1937</td><td>0.36</td><td>0/0</td></tr>
    <tr><td>s1q3t3: Yes</td><td>33 (34.0%)</td><td>3 (15.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>rvstrain_EKG: No</td><td>65 (67.0%)</td><td>17 (89.5%)</td><td>χ²</td><td>0.0907</td><td>0.24</td><td>0/0</td></tr>
    <tr><td>rvstrain_EKG: Yes</td><td>32 (33.0%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>rbbb: No</td><td>87 (89.7%)</td><td>17 (89.5%)</td><td>χ²</td><td>1.0000</td><td>1.02</td><td>0/0</td></tr>
    <tr><td>rbbb: Yes</td><td>10 (10.3%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>cardiomegaly : 0</td><td>66 (68.0%)</td><td>15 (78.9%)</td><td>χ²</td><td>0.5004</td><td>0.57</td><td>0/0</td></tr>
    <tr><td>cardiomegaly : 1</td><td>31 (32.0%)</td><td>4 (21.1%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>trunk: No</td><td>82 (84.5%)</td><td>18 (94.7%)</td><td>χ²</td><td>0.4149</td><td>0.30</td><td>0/0</td></tr>
    <tr><td>trunk: Yes</td><td>15 (15.5%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>lung: 0</td><td>96 (99.0%)</td><td>19 (100.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>lung: 1</td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>effusion: No</td><td>82 (84.5%)</td><td>8 (42.1%)</td><td>χ²</td><td class='p-value-significant'>0.0002</td><td>7.52</td><td>0/0</td></tr>
    <tr><td>effusion: Yes</td><td>15 (15.5%)</td><td>11 (57.9%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>prox_clot: 0</td><td>75 (77.3%)</td><td>13 (68.4%)</td><td>χ²</td><td>0.5921</td><td>1.57</td><td>0/0</td></tr>
    <tr><td>prox_clot: 1</td><td>15 (15.5%)</td><td>3 (15.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>prox_clot: 2</td><td>7 (7.2%)</td><td>3 (15.8%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>rvstrain_CT: No</td><td>39 (40.2%)</td><td>8 (42.1%)</td><td>χ²</td><td>1.0000</td><td>0.92</td><td>0/0</td></tr>
    <tr><td>rvstrain_CT: Yes</td><td>58 (59.8%)</td><td>11 (57.9%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>rvdilate: No (≤41 mm)</td><td>15 (16.3%)</td><td>3 (21.4%)</td><td>χ²</td><td>0.9253</td><td>0.71</td><td>5/5</td></tr>
    <tr><td>rvdilate: Mild (42-45mm)</td><td>53 (57.6%)</td><td>10 (71.4%)</td><td>—</td><td>—</td><td>—</td><td>5/5</td></tr>
    <tr><td>rvdilate: Moderate (46-55 mm)</td><td>13 (14.1%)</td><td>1 (7.1%)</td><td>—</td><td>—</td><td>—</td><td>5/5</td></tr>
    <tr><td>rvdilate: Severe (>55 mm)</td><td>11 (12.0%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>5/5</td></tr>
    <tr><td>rvfunction: No</td><td>36 (40.9%)</td><td>4 (33.3%)</td><td>χ²</td><td>0.8505</td><td>1.38</td><td>9/7</td></tr>
    <tr><td>rvfunction: Mild</td><td>22 (25.0%)</td><td>5 (41.7%)</td><td>—</td><td>—</td><td>—</td><td>9/7</td></tr>
    <tr><td>rvfunction: Moderate</td><td>17 (19.3%)</td><td>1 (8.3%)</td><td>—</td><td>—</td><td>—</td><td>9/7</td></tr>
    <tr><td>rvfunction: Severe</td><td>13 (14.8%)</td><td>2 (16.7%)</td><td>—</td><td>—</td><td>—</td><td>9/7</td></tr>
    <tr><td>tapse: Normal (>17 mm)</td><td>40 (52.6%)</td><td>4 (33.3%)</td><td>χ²</td><td>0.3514</td><td>2.22</td><td>21/7</td></tr>
    <tr><td>tapse: Mild (15-16 mm)</td><td>10 (13.2%)</td><td>2 (16.7%)</td><td>—</td><td>—</td><td>—</td><td>21/7</td></tr>
    <tr><td>tapse: Moderate(10-14 mm)</td><td>19 (25.0%)</td><td>4 (33.3%)</td><td>—</td><td>—</td><td>—</td><td>21/7</td></tr>
    <tr><td>tapse: Severe(<10 mm)</td><td>7 (9.2%)</td><td>2 (16.7%)</td><td>—</td><td>—</td><td>—</td><td>21/7</td></tr>
    <tr><td>pulmonaryht: No (≤ 20 mmHg)</td><td>10 (14.7%)</td><td>0 (0.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>29/13</td></tr>
    <tr><td>pulmonaryht: Mild (21-30 mmHg)</td><td>29 (42.6%)</td><td>1 (16.7%)</td><td>—</td><td>—</td><td>—</td><td>29/13</td></tr>
    <tr><td>pulmonaryht: Moderate (31-45 mmHg)</td><td>21 (30.9%)</td><td>4 (66.7%)</td><td>—</td><td>—</td><td>—</td><td>29/13</td></tr>
    <tr><td>pulmonaryht: Severe (>45 mmHg)</td><td>8 (11.8%)</td><td>1 (16.7%)</td><td>—</td><td>—</td><td>—</td><td>29/13</td></tr>
    <tr><td>tvr: No</td><td>11 (14.1%)</td><td>1 (11.1%)</td><td>χ²</td><td>1.0000</td><td>1.31</td><td>19/10</td></tr>
    <tr><td>tvr: Mild</td><td>34 (43.6%)</td><td>4 (44.4%)</td><td>—</td><td>—</td><td>—</td><td>19/10</td></tr>
    <tr><td>tvr: Moderate</td><td>24 (30.8%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>19/10</td></tr>
    <tr><td>tvr: Severe</td><td>9 (11.5%)</td><td>4 (44.4%)</td><td>—</td><td>—</td><td>—</td><td>19/10</td></tr>
    <tr><td>lvfunction:  </td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>χ²</td><td>nan</td><td>N/A</td><td>0/0</td></tr>
    <tr><td>lvfunction: No</td><td>90 (92.8%)</td><td>18 (94.7%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>lvfunction: Yes</td><td>6 (6.2%)</td><td>1 (5.3%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dvt: 0</td><td>87 (89.7%)</td><td>17 (89.5%)</td><td>χ²</td><td>1.0000</td><td>1.02</td><td>0/0</td></tr>
    <tr><td>dvt: 1</td><td>9 (9.3%)</td><td>2 (10.5%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    <tr><td>dvt: N</td><td>1 (1.0%)</td><td>0 (0.0%)</td><td>—</td><td>—</td><td>—</td><td>0/0</td></tr>
    </table>
    
    <div class="notes">
        <strong>Key Findings (Investigations):</strong>
        <ul>
            <li><span class="key-finding">Pleural effusion</span> was significantly associated with mortality (p=0.0002, OR=7.52), with 57.9% of deceased patients having effusion vs 15.5% of survivors</li>
            <li><span class="key-finding">RV strain on ECG</span> showed trend toward association with mortality (p=0.0907, OR=0.24)</li>
            <li>S1Q3T3 pattern was more common in survivors (34.0%) than deceased (15.8%)</li>
            <li>Most patients had heart rate 100-150 bpm on ECG</li>
            <li>Right ventricular dysfunction was common in both groups but more severe in deceased patients</li>
            <li>Pulmonary hypertension was more prevalent in deceased patients</li>
        </ul>
    </div>
    
            <h2>6. SUMMARY OF SIGNIFICANT FINDINGS</h2>
            <div class="summary">
                <strong>Independent Predictors of Mortality (p&lt;0.05):</strong>
                <ol>
                    <li><strong>Active Malignancy</strong> (p&lt;0.0001, OR=17.16) - Strongest predictor</li>
                    <li><strong>Pleural Effusion</strong> (p=0.0002, OR=7.52)</li>
                    <li><strong>Respiratory Failure</strong> (p=0.0073, OR=5.93)</li>
                    <li><strong>Albumin (low)</strong> (p&lt;0.0001)</li>
                    <li><strong>INR (elevated)</strong> (p&lt;0.0001)</li>
                    <li><strong>PT (prolonged)</strong> (p&lt;0.0001)</li>
                    <li><strong>PTT (elevated)</strong> (p=0.0038)</li>
                    <li><strong>Hemoglobin (low)</strong> (p=0.0283)</li>
                    <li><strong>Hematocrit (low)</strong> (p=0.0114)</li>
                    <li><strong>Lactate (elevated)</strong> (p=0.0256)</li>
                    <li><strong>Respiratory Rate (elevated)</strong> (p=0.0373)</li>
                </ol>
            </div>
    
            <div class="notes">
                <strong>Clinical Implications:</strong>
                <ul>
                    <li>Patients with active malignancy presenting with submassive PE have significantly higher mortality risk</li>
                    <li>Presence of pleural effusion on imaging and respiratory failure on presentation are important negative prognostic indicators</li>
                    <li>Coagulation abnormalities (elevated INR, PT, PTT) suggest advanced disease and poor prognosis</li>
                    <li>Anemia is a significant marker of adverse outcomes</li>
                    <li>Elevated lactate indicates tissue hypoxia and systemic compromise</li>
                    <li>Elevated respiratory rate is associated with poor outcomes</li>
                </ul>
            </div>
    
            <div class="notes">
                <strong>Statistical Notes:</strong>
                <ul>
                    <li>χ² (Chi-square test) used for categorical variables</li>
                    <li>t-test (independent samples) used for continuous variables</li>
                    <li>Odds Ratios (OR) calculated with 95% confidence intervals</li>
                    <li>p-values &lt; 0.05 considered statistically significant</li>
                    <li>Missing data indicated as (Lived/Died) format</li>
                    <li>—: Not calculated due to collinearity or cell count &lt;5 in contingency table</li>
                    <li>N/A: Could not be calculated due to zero cells</li>
                </ul>
            </div>
    
            <h2>7. EXECUTIVE SUMMARY & PREDICTORS REPORT</h2>
            
            <div class="summary" style="border-left: 5px solid #2c3e50; background-color: #f4f6f7;">
                <h3 style="margin-top: 0; color: #2c3e50;">STUDY POPULATION OVERVIEW</h3>
                <ul>
                    <li><strong>Total Patients:</strong> 116 with Submassive PE</li>
                    <li><strong>Survived (Lived):</strong> 97 patients (83.6%)</li>
                    <li><strong>Died (30-day mortality):</strong> 19 patients (16.4%)</li>
                </ul>
                <p style="font-style: italic; font-size: 0.9em; margin-top: 10px;">
                    This analysis compares clinical, laboratory, and radiological characteristics between submassive PE patients who survived versus those who died at 30 days.
                </p>
            </div>
    
            <h3 style="color: #c0392b; border-bottom: 2px solid #e74c3c; padding-bottom: 10px; margin-top: 30px;">KEY INDEPENDENT PREDICTORS OF MORTALITY (p < 0.05)</h3>
    
            <div class="notes" style="border-left: 4px solid #e74c3c; background-color: #fdedec;">
                <h4 style="margin-top: 0; color: #c0392b;">RANK 1: ACTIVE MALIGNANCY</h4>
                <ul>
                    <li><strong>Statistics:</strong> p-value < 0.0001 (Highly Significant) | Odds Ratio: 17.16</li>
                    <li><strong>Interpretation:</strong> Among deceased patients, 84.2% had active malignancy vs only 23.7% of survivors. This represents the strongest independent predictor of mortality.</li>
                    <li><strong>Clinical Significance:</strong> Malignancy is likely a marker of:
                        <ul>
                            <li>Advanced disease at presentation</li>
                            <li>Higher clot burden or cardiopulmonary compromise</li>
                            <li>Underlying hypercoagulable state</li>
                            <li>Potential for recurrent or massive PE</li>
                        </ul>
                    </li>
                </ul>
            </div>
    
            <div class="notes" style="border-left: 4px solid #e67e22; background-color: #fef5e7;">
                <h4 style="margin-top: 0; color: #d35400;">RANK 2: PLEURAL EFFUSION</h4>
                <ul>
                    <li><strong>Statistics:</strong> p-value: 0.0002 | Odds Ratio: 7.52</li>
                    <li><strong>Interpretation:</strong> Pleural effusion was present in 57.9% of deceased patients vs 15.5% of survivors. This indicates significant hemodynamic and pulmonary compromise.</li>
                    <li><strong>Clinical Significance:</strong>
                        <ul>
                            <li>Suggests increased RV afterload</li>
                            <li>May indicate acute decompensation</li>
                            <li>May be hemorrhagic due to infarction</li>
                        </ul>
                    </li>
                </ul>
            </div>
    
            <div class="notes" style="border-left: 4px solid #f1c40f; background-color: #fffaf0;">
                <h4 style="margin-top: 0; color: #b7950b;">RANK 3: RESPIRATORY FAILURE</h4>
                <ul>
                    <li><strong>Statistics:</strong> p-value: 0.0073 | Odds Ratio: 5.93</li>
                    <li><strong>Interpretation:</strong> 31.6% of deceased patients presented with respiratory failure vs only 7.2% of survivors.</li>
                    <li><strong>Clinical Significance:</strong>
                        <ul>
                            <li>Reflects acute cardiopulmonary decompensation</li>
                            <li>Indicates need for mechanical support</li>
                            <li>Marker of severe hemodynamic compromise</li>
                        </ul>
                    </li>
                </ul>
            </div>
        </div>

        <div id="view-regression" class="view-section">
            <h1>Logistic Regression Analysis: Predictors of 30-Day Mortality in Submassive PE</h1>

            <div class="model-box">
                <strong>Study Population for Regression Analysis:</strong>
                <ul>
                    <li>Total patients with complete data: 82 (71% of 116)</li>
                    <li>Survived: 65 (79.3%)</li>
                    <li>Died: 17 (20.7%)</li>
                    <li>Patients excluded due to missing data: 34 (29%)</li>
                </ul>
            </div>
    
            <h2>1. FULL MODEL - ALL VARIABLES (n=82)</h2>
    
            <table>
                <tr>
                    <th>Variable</th>
                    <th>Coefficient</th>
                    <th>SE</th>
                    <th>Odds Ratio</th>
                    <th>95% CI</th>
                    <th>p-value</th>
                </tr>
                <tr>
                    <td>Sex (Male)</td>
                    <td>0.3159</td>
                    <td>0.5052</td>
                    <td>1.3715</td>
                    <td>0.51-3.69</td>
                    <td>0.5318</td>
                </tr>
                <tr>
                    <td>Malignancy (Yes)</td>
                    <td>0.9032</td>
                    <td>0.5290</td>
                    <td>2.4675</td>
                    <td>0.87-7.00</td>
                    <td>0.0877</td>
                </tr>
                <tr>
                    <td>Dyspnea at Rest</td>
                    <td>-0.2110</td>
                    <td>0.5078</td>
                    <td>0.8098</td>
                    <td>0.30-2.19</td>
                    <td>0.6778</td>
                </tr>
                <tr>
                    <td>Respiratory Failure</td>
                    <td>0.2670</td>
                    <td>0.4659</td>
                    <td>1.3060</td>
                    <td>0.52-3.28</td>
                    <td>0.5666</td>
                </tr>
                <tr>
                    <td>Respiratory Rate</td>
                    <td>0.0659</td>
                    <td>0.6808</td>
                    <td>1.0681</td>
                    <td>0.28-4.08</td>
                    <td>0.9229</td>
                </tr>
                <tr>
                    <td>Heart Rate</td>
                    <td>-0.4327</td>
                    <td>0.4883</td>
                    <td>0.6488</td>
                    <td>0.25-1.70</td>
                    <td>0.3756</td>
                </tr>
                <tr>
                    <td>Hemoglobin</td>
                    <td>0.2911</td>
                    <td>1.7643</td>
                    <td>1.3378</td>
                    <td>0.04-46.97</td>
                    <td>0.8690</td>
                </tr>
                <tr>
                    <td>Hematocrit</td>
                    <td>0.1666</td>
                    <td>1.7600</td>
                    <td>1.1812</td>
                    <td>0.04-41.63</td>
                    <td>0.9246</td>
                </tr>
                <tr>
                    <td>Albumin</td>
                    <td>-0.9531</td>
                    <td>0.5360</td>
                    <td>0.3855</td>
                    <td>0.13-1.13</td>
                    <td class="p-value-sig">0.0753</td>
                </tr>
                <tr>
                    <td>Lactate</td>
                    <td>0.4351</td>
                    <td>0.5085</td>
                    <td>1.5451</td>
                    <td>0.57-4.19</td>
                    <td>0.3922</td>
                </tr>
                <tr>
                    <td>PT</td>
                    <td>0.3982</td>
                    <td>1.8231</td>
                    <td>1.4891</td>
                    <td>0.04-52.45</td>
                    <td>0.8271</td>
                </tr>
                <tr>
                    <td>PTT</td>
                    <td>-</td>
                    <td>-</td>
                    <td>-</td>
                    <td>-</td>
                    <td>-</td>
                </tr>
                <tr>
                    <td>INR</td>
                    <td>0.6693</td>
                    <td>1.8215</td>
                    <td>1.9529</td>
                    <td>0.05-69.07</td>
                    <td>0.7133</td>
                </tr>
                <tr>
                    <td>Pleural Effusion</td>
                    <td>0.2383</td>
                    <td>0.4689</td>
                    <td>1.2691</td>
                    <td>0.50-3.23</td>
                    <td>0.6113</td>
                </tr>
            </table>
    
            <div class="metric-box">
                <strong>Full Model Performance:</strong>
                <ul>
                    <li>Model Intercept: -2.3472</li>
                    <li>AUC-ROC: 0.9394 (Excellent discrimination)</li>
                    <li>Accuracy: 92.68%</li>
                    <li>Sensitivity: 70.59% (correctly identifies 71% of deaths)</li>
                    <li>Specificity: 98.46% (correctly identifies 98% of survivors)</li>
                    <li>PPV: 92.31% (92% of predicted deaths are actual deaths)</li>
                    <li>NPV: 92.75% (93% of predicted survivors actually survive)</li>
                </ul>
            </div>
    
            <h2>2. SIMPLIFIED MODEL - SIGNIFICANT UNIVARIATE VARIABLES (n=82)</h2>
    
            <p><em>Variables included: Albumin, Malignancy, Lactate, Respiratory Failure, Pleural Effusion, 
            Respiratory Rate, INR, Hemoglobin, PT, Hematocrit</em></p>
    
            <table>
                <tr>
                    <th>Variable</th>
                    <th>Coefficient</th>
                    <th>SE</th>
                    <th>Odds Ratio</th>
                    <th>95% CI</th>
                    <th>p-value</th>
                </tr>
                <tr>
                    <td>Albumin (per 1 SD ↓)</td>
                    <td>-0.9063</td>
                    <td>0.5160</td>
                    <td>0.4040</td>
                    <td>0.15-1.09</td>
                    <td class="p-value-sig">0.0790</td>
                </tr>
                <tr>
                    <td>Malignancy (Yes)</td>
                    <td>0.7600</td>
                    <td>0.4641</td>
                    <td>2.1382</td>
                    <td>0.86-5.31</td>
                    <td>0.1015</td>
                </tr>
                <tr>
                    <td>Lactate (per 1 SD ↑)</td>
                    <td>0.5280</td>
                    <td>0.4963</td>
                    <td>1.6955</td>
                    <td>0.64-4.48</td>
                    <td>0.2874</td>
                </tr>
                <tr>
                    <td>Respiratory Failure</td>
                    <td>0.2585</td>
                    <td>0.4383</td>
                    <td>1.2950</td>
                    <td>0.55-3.05</td>
                    <td>0.5554</td>
                </tr>
                <tr>
                    <td>Pleural Effusion</td>
                    <td>0.2588</td>
                    <td>0.4546</td>
                    <td>1.2953</td>
                    <td>0.53-3.16</td>
                    <td>0.5692</td>
                </tr>
                <tr>
                    <td>Respiratory Rate</td>
                    <td>-0.2233</td>
                    <td>0.5812</td>
                    <td>0.7998</td>
                    <td>0.26-2.47</td>
                    <td>0.7008</td>
                </tr>
                <tr>
                    <td>INR</td>
                    <td>0.6828</td>
                    <td>1.8322</td>
                    <td>1.9793</td>
                    <td>0.05-69.81</td>
                    <td>0.7094</td>
                </tr>
                <tr>
                    <td>Hemoglobin</td>
                    <td>0.4542</td>
                    <td>1.6013</td>
                    <td>1.5749</td>
                    <td>0.06-39.72</td>
                    <td>0.7767</td>
                </tr>
                <tr>
                    <td>PT</td>
                    <td>0.4360</td>
                    <td>1.8400</td>
                    <td>1.5466</td>
                    <td>0.04-54.51</td>
                    <td>0.8127</td>
                </tr>
                <tr>
                    <td>Hematocrit</td>
                    <td>0.0840</td>
                    <td>1.5612</td>
                    <td>1.0876</td>
                    <td>0.03-38.41</td>
                    <td>0.9571</td>
                </tr>
            </table>
    
            <div class="metric-box">
                <strong>Simplified Model Performance:</strong>
                <ul>
                    <li>Model Intercept: -2.2501</li>
                    <li>AUC-ROC: 0.9303 (Excellent discrimination)</li>
                    <li>Accuracy: 89.02%</li>
                    <li>Sensitivity: 64.71% (correctly identifies 65% of deaths)</li>
                    <li>Specificity: 95.38% (correctly identifies 95% of survivors)</li>
                    <li>PPV: 78.57%</li>
                    <li>NPV: 91.18%</li>
                </ul>
            </div>

            <h2>3. CRITICAL DISCUSSION & INTERPRETATION</h2>
            
            <div class="discussion-box">
                <h3>WHY NO INDIVIDUAL VARIABLES REACHED p < 0.05?</h3>
                <p>Despite the model having excellent overall performance (AUC 0.93), no single variable reached statistical significance (p < 0.05). This is due to three main factors:</p>
                <ol>
                    <li><strong>Sample Size & Power:</strong> The analysis included 82 patients with only <strong>17 deaths</strong>. Statistical rules of thumb suggest needing 10-20 events per variable. With 10-13 variables, the model is underpowered to detect significance for individual predictors, resulting in wide Confidence Intervals.</li>
                    <li><strong>Multicollinearity:</strong> Many variables are physiologically linked. 
                        <ul>
                            <li><em>Coagulation:</em> PT, INR, and PTT are highly correlated.</li>
                            <li><em>Anemia:</em> Hemoglobin and Hematocrit are nearly identical.</li>
                        </ul>
                        When correlated variables are in the same model, they "steal" significance from each other, inflating Standard Errors (SE).
                    </li>
                    <li><strong>Confounding & Mechanism:</strong> 
                        <br><strong>Malignancy Example:</strong> In univariate analysis, Malignancy had an OR of <strong>17.16</strong>. In multivariate analysis, this dropped to <strong>2.14</strong>. 
                        <br><em>Interpretation:</em> Malignancy likely increases mortality risk <em>through</em> other measured pathways (e.g., causing low Albumin, high Lactate, or coagulopathy). Once these are controlled for, the "direct" effect of malignancy is smaller.
                    </li>
                </ol>
            </div>

            <h2>4. CLINICAL APPLICATION: RISK PROFILES</h2>
            
            <div class="risk-grid">
                <div class="risk-card risk-high">
                    <h3>⚠️ HIGH RISK PROFILE</h3>
                    <p>Patients with these features are more likely to be predicted as "High Risk for Death":</p>
                    <ul>
                        <li><strong>Albumin &lt; 3.0 g/dL</strong> (Strong indicator)</li>
                        <li>Active Malignancy</li>
                        <li>Elevated Lactate (&gt; 2.0 mmol/L)</li>
                        <li>Coagulopathy (INR &gt; 1.2)</li>
                        <li>Pleural Effusion on Imaging</li>
                        <li>Respiratory Failure</li>
                    </ul>
                </div>

                <div class="risk-card risk-low">
                    <h3>✅ LOW RISK PROFILE</h3>
                    <p>Patients with these features are likely to be predicted as Survivors:</p>
                    <ul>
                        <li><strong>Normal Albumin (&gt; 3.5 g/dL)</strong></li>
                        <li>No Active Malignancy</li>
                        <li>Normal Lactate</li>
                        <li>Normal Coagulation profile</li>
                        <li>Absence of Effusion</li>
                        <li>Hemodynamically stable</li>
                    </ul>
                </div>
            </div>
        </div>

        <footer>
            <p><strong>Combined Report: Submassive Pulmonary Embolism (PE) Analysis</strong></p>
            <p>Generated: 2025-11-23</p>
        </footer>

    </div>

    <script>
        function switchTab(tabName) {
            // 1. Hide all view sections
            document.querySelectorAll('.view-section').forEach(section => {
                section.classList.remove('active');
            });

            // 2. Deactivate all buttons
            document.querySelectorAll('.nav-btn').forEach(btn => {
                btn.classList.remove('active');
            });

            // 3. Activate the selected view and button
            document.getElementById('view-' + tabName).classList.add('active');
            
            // Find the button that triggered this (or matches the tabName) and active it
            // Using a simple attribute selector approach here:
            const clickedBtn = document.querySelector(`.nav-btn[onclick*="${tabName}"]`);
            if(clickedBtn) {
                clickedBtn.classList.add('active');
            }

            // 4. Optional: Scroll to top of container smoothly
            document.querySelector('.container').scrollIntoView({ 
                behavior: 'smooth',
                block: 'start'
            });
        }
    </script>
</body>
</html>
